CA2444876A1 - Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists - Google Patents

Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists Download PDF

Info

Publication number
CA2444876A1
CA2444876A1 CA002444876A CA2444876A CA2444876A1 CA 2444876 A1 CA2444876 A1 CA 2444876A1 CA 002444876 A CA002444876 A CA 002444876A CA 2444876 A CA2444876 A CA 2444876A CA 2444876 A1 CA2444876 A1 CA 2444876A1
Authority
CA
Canada
Prior art keywords
use according
lhrh antagonist
methyl
treatment
monthly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002444876A
Other languages
English (en)
French (fr)
Inventor
Jurgen Engel
Rainer Voegeli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Zentaris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris AG filed Critical Zentaris AG
Publication of CA2444876A1 publication Critical patent/CA2444876A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CA002444876A 2001-04-30 2002-04-27 Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists Abandoned CA2444876A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28743401P 2001-04-30 2001-04-30
US60/287,434 2001-04-30
PCT/EP2002/004677 WO2002102401A1 (en) 2001-04-30 2002-04-27 Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists

Publications (1)

Publication Number Publication Date
CA2444876A1 true CA2444876A1 (en) 2002-12-27

Family

ID=23102886

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002444876A Abandoned CA2444876A1 (en) 2001-04-30 2002-04-27 Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists

Country Status (27)

Country Link
US (1) US7288517B2 (enExample)
EP (1) EP1392348B1 (enExample)
JP (1) JP2004529207A (enExample)
KR (1) KR20040000446A (enExample)
CN (1) CN1317030C (enExample)
AT (1) ATE400287T1 (enExample)
AU (1) AU2002310788B2 (enExample)
BG (1) BG108339A (enExample)
BR (1) BR0209290A (enExample)
CA (1) CA2444876A1 (enExample)
CZ (1) CZ20033167A3 (enExample)
DE (1) DE60227507D1 (enExample)
DK (1) DK1392348T3 (enExample)
ES (1) ES2307760T3 (enExample)
HU (1) HUP0400067A2 (enExample)
IL (1) IL156777A0 (enExample)
MX (1) MXPA03008666A (enExample)
NO (1) NO20034322D0 (enExample)
NZ (1) NZ544417A (enExample)
PL (1) PL362319A1 (enExample)
PT (1) PT1392348E (enExample)
RU (1) RU2319501C2 (enExample)
SI (1) SI1392348T1 (enExample)
SK (1) SK14512003A3 (enExample)
UA (1) UA80679C2 (enExample)
WO (1) WO2002102401A1 (enExample)
ZA (1) ZA200305326B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
US20020077327A1 (en) * 1999-09-23 2002-06-20 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
AU7102201A (en) * 2000-07-05 2002-01-14 Yamanouchi Pharma Co Ltd Propane-1,3-dione derivatives
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
EP1752452A4 (en) * 2004-06-04 2010-07-14 Astellas Pharma Inc DERIVATIVE OF PROPANE-1, 3-DIONE OR ITS SALT
US20080171736A1 (en) * 2004-12-23 2008-07-17 Gregory Christopher W Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists
WO2006071274A2 (en) * 2004-12-23 2006-07-06 Voyager Pharmaceutical Corporation Leuprolide acetate and acetylcholinesterase inhibitors or nmda receptor antagonists for the treatment of alzheimer’s disease
RU2404973C2 (ru) * 2005-03-31 2010-11-27 Астеллас Фарма Инк. Производное соединение пропан-1,3-диона или его соль
US8642598B2 (en) * 2006-10-21 2014-02-04 Abbvie Inc. Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
WO2009039983A2 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
WO2009043441A1 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag D-ala-gln-octadecyl ester as a therapeutic agent
EP2095818A1 (en) * 2008-02-29 2009-09-02 AEterna Zentaris GmbH Use of LHRH antagonists at non-castrating doses
EP2307040B1 (en) * 2008-05-29 2015-09-09 Isr Immune System Regulation Ab Use of gnrh and sex hormones for treating viral disease, in particular hiv/aids
CN103119035B (zh) 2010-09-27 2015-09-30 雅培股份有限两合公司 杂环化合物和它们作为糖原合成酶激酶-3抑制剂的用途
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
EP3560555A1 (en) * 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases
WO2025155903A1 (en) * 2024-01-19 2025-07-24 Temple University-Of The Commonwealth System Of Higher Education Compositions of antioxidant translation modulators for treating neurodegenerative disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135743A (en) 1960-06-29 1964-06-02 Sterling Drug Inc Steroido[2. 3-d]isoxazoles and preparation thereof
JP2000511532A (ja) 1996-05-20 2000-09-05 メルク エンド カンパニー インコーポレーテッド 性腺刺激ホルモン放出ホルモンのアンタゴニスト
DE19911771B4 (de) 1999-03-17 2006-03-30 Zentaris Gmbh LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung
WO2000069859A1 (en) 1999-05-14 2000-11-23 Neurocrine Biosciences, Inc. Imidazo- and pyrrolo[1,2-a]pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists
CA2309395A1 (en) 1999-06-04 2000-12-04 Richard Lloyd Bowen Methods for preventing and treating alzheimer's disease
ES2249302T3 (es) * 1999-10-15 2006-04-01 Neurocrine Biosciences, Inc. Antagonistas del receptor de la hormona liberadora de gonadotropina y sus metodos de uso relacionados.
WO2001078780A1 (en) 2000-04-13 2001-10-25 Takeda Chemical Industries, Ltd. Preventives/remedies for alzheimer's disease
AU7102201A (en) 2000-07-05 2002-01-14 Yamanouchi Pharma Co Ltd Propane-1,3-dione derivatives

Also Published As

Publication number Publication date
EP1392348B1 (en) 2008-07-09
KR20040000446A (ko) 2004-01-03
CN1317030C (zh) 2007-05-23
ATE400287T1 (de) 2008-07-15
IL156777A0 (en) 2004-02-08
JP2004529207A (ja) 2004-09-24
EP1392348A1 (en) 2004-03-03
NO20034322L (no) 2003-09-26
ZA200305326B (en) 2003-07-30
HK1072000A1 (en) 2005-08-12
MXPA03008666A (es) 2004-10-15
ES2307760T3 (es) 2008-12-01
RU2319501C2 (ru) 2008-03-20
CN1575185A (zh) 2005-02-02
WO2002102401A1 (en) 2002-12-27
NO20034322D0 (no) 2003-09-26
CZ20033167A3 (cs) 2004-08-18
DE60227507D1 (de) 2008-08-21
RU2003134949A (ru) 2005-02-10
US7288517B2 (en) 2007-10-30
US20020177556A1 (en) 2002-11-28
SK14512003A3 (sk) 2004-08-03
AU2002310788B2 (en) 2007-04-05
UA80679C2 (en) 2007-10-25
PL362319A1 (en) 2004-10-18
NZ544417A (en) 2008-03-28
SI1392348T1 (sl) 2008-12-31
DK1392348T3 (da) 2008-09-29
HUP0400067A2 (hu) 2004-04-28
BR0209290A (pt) 2004-07-13
BG108339A (bg) 2004-11-30
PT1392348E (pt) 2008-09-09

Similar Documents

Publication Publication Date Title
EP1392348B1 (en) Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists
AU2002310788A1 (en) Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists
EP1663236B1 (en) Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and a biphosphonate
DE69927705T2 (de) Verwendung von acetylcholinesterase inhibitoren zur modulierung der hypothalamus-hypophysen-gonadenachse
HU202118B (en) Process for producing medical compositions comprising dipeptides with noothropic effect
US12268679B1 (en) Compositions and methods for epidural administration of MCOPPB for pain relief
KR20000029647A (ko) 양극성장애의치료방법
HK1072000B (en) Treatment of alzheimer's diseases with intemediate doses of lhrh antagonists
KR102494794B1 (ko) 여성 성기능장애의 치료를 위한 약학 조성물 및 방법
CA3191653A1 (en) Mepyramine for use in the topical treatment of neuropathic pain
US20040157772A1 (en) Use of a gatran for the manufacture of a medicament of the treatment of pulmonary fibrosis
JPH04506969A (ja) 成人男性における不妊症又は生殖能力低下の治療方法および該方法のための製剤の使用
WO1995017189A1 (en) NEW USE OF δ-OPIOID RECEPTOR ANTAGONISTS
HK1090294B (en) Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl] phenyl)pyridine-3-sulphonamide and a biphosphonate
EP0998923A1 (en) Use of 5-HT7 receptor agonists for the treatment or prophylaxis of ischemias
HK1126131A (en) Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an lhrh analogue and/or a bisphosphonate
JPH09136843A (ja) 血圧上昇薬
AU2002305989A1 (en) The use of a gatran for the manufacture of a medicament for the treatment of pulmonary fibrosis

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued